quinuclidines has been researched along with Cognition Disorders in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.88) | 18.7374 |
| 1990's | 1 (5.88) | 18.2507 |
| 2000's | 5 (29.41) | 29.6817 |
| 2010's | 9 (52.94) | 24.3611 |
| 2020's | 1 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Hort, J; Klimova, B; Kuca, K; Nepovimova, E; Novotny, M; Oleksak, P; Patocka, J; Pavlik, J; Valis, M | 1 |
| Bertrand, E; Boiaryna, L; Buron, F; Chalon, S; Chartier, A; Deloye, JB; Guilloteau, D; Gulhan, Z; Mothes, C; Ouach, A; Page, G; Percina, N; Pin, F; Rodrigues, N; Routier, S; Serriere, S; Suzenet, F; Tangpong, P; Vercouillie, J | 1 |
| Bauer, LO; Dgetluck, N; Gawryl, M; Hilt, DC; Palfreyman, M; Preskorn, SH | 1 |
| Babri, S; Mahmoudi, J; Sadigh-Eteghad, S; Shanehbandi, D; Talebi, M | 1 |
| Dgetluck, N; Gawryl, M; Hilt, DC; Keefe, RS; Koenig, G; Lombardo, I; Meltzer, HA; Moebius, HJ | 1 |
| Haig, G; Othman, AA; Wang, D; Zhao, J | 1 |
| Benitex, Y; Bristow, LJ; Chen, P; Cook, J; Daly, C; Easton, AE; Gallagher, L; Hendricson, A; Iwuagwu, C; Jones, KM; King, D; Li, YW; Lidge, R; Lodge, NJ; Macor, JE; Molski, T; Morgan, D; Olson, R; Pieschl, R; Post-Munson, D; Sivarao, DV; Westphal, R; Zaczek, R | 1 |
| Berry, S; Gault, LM; Lenz, RA; Meier, A; Othman, AA; Pritchett, Y; Ritchie, CW; Robieson, WZ; Tang, Q | 1 |
| Bencherif, M; Gatto, GJ; Hauser, TA; Hesse, RA; Jordan, KG; Kucinski, A; Lippiello, PM; Papke, RL; Stachowiak, EK; Stachowiak, MK; Wersinger, SR | 1 |
| Bolodeoku, J; Edgar, C; Tretter, RN; Wesnes, KA | 1 |
| Jakobsen, SM; Kersten, H; Molden, E | 1 |
| Benson, L; Dull, G; Fedorov, NB; Genus, JF; Hammond, PS; Hauser, TA; James, JW; Kombo, DC; Mazurov, AA; Miao, L; Miller, CH; Sidach, S; Xiao, Y; Yohannes, D | 1 |
| Fujio, M; Hashimoto, K; Horikawa, T; Katayama, J; Kuriyama, M; Maeda, J; Murozono, T; Numata, A; Satoh, H; Shiigi, Y; Takanashi, S; Tanaka, H; Tatsumi, R | 1 |
| Arneric, SP; Carey, G; Cook, KK; Cortes-Burgos, LA; Franklin, S; Gold, LH; Groppi, VE; Hajos, M; Hanchar, AJ; Higdon, NR; Hoffmann, WE; Hurst, RS; Jacobsen, EJ; Jia, S; Kalgutkar, AS; Myers, JK; Olson, KL; Raub, TJ; Reitz, SC; Rogers, BN; Sands, SB; Soglia, JR; Staton, BA; Thornburgh, BA; Walker, DP; Wall, TM; Walters, RR; Wishka, DG; Wolfe, ML; Wong, EH; Yates, KM; Zhao, SX | 1 |
| Boess, FG; De Vry, J; Erb, C; Flessner, T; Hendrix, M; Koenig, G; Luithle, J; Methfessel, C; Riedl, B; Schnizler, K; van der Staay, FJ; van Kampen, M; Wiese, WB | 1 |
| Brandeis, R; Fisher, A; Gurwitz, D; Haring, R; Heldman, E; Karton, I; Levy, A; Pittel, Z; Sapir, M | 1 |
| Brandeis, R; Dachir, S; Fisher, A; Heldman, E; Karton, I; Levy, A; Pittel, Z; Sapir, M | 1 |
1 review(s) available for quinuclidines and Cognition Disorders
| Article | Year |
|---|---|
Neuropharmacology of Cevimeline and Muscarinic Drugs-Focus on Cognition and Neurodegeneration.
Topics: Animals; Cognition Disorders; Humans; Muscarinic Agonists; Neurodegenerative Diseases; Neuropharmacology; Pharmaceutical Preparations; Quinuclidines; Thiophenes | 2021 |
5 trial(s) available for quinuclidines and Cognition Disorders
| Article | Year |
|---|---|
Normalizing effects of EVP-6124, an α-7 nicotinic partial agonist, on event-related potentials and cognition: a proof of concept, randomized trial in patients with schizophrenia.
Topics: Adolescent; Adult; alpha7 Nicotinic Acetylcholine Receptor; Antipsychotic Agents; Cognition; Cognition Disorders; Double-Blind Method; Drug Therapy, Combination; Evoked Potentials; Female; Humans; Male; Middle Aged; Quinuclidines; Schizophrenia; Thiophenes; Treatment Outcome; Young Adult | 2014 |
Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia.
Topics: Adolescent; Adult; alpha7 Nicotinic Acetylcholine Receptor; Antipsychotic Agents; Cognition; Cognition Disorders; Double-Blind Method; Female; Humans; Male; Middle Aged; Nicotinic Agonists; Psychiatric Status Rating Scales; Psychotropic Drugs; Quinuclidines; Schizophrenia; Schizophrenic Psychology; Thiophenes; Treatment Outcome; Young Adult | 2015 |
The α7 Nicotinic Agonist ABT-126 in the Treatment of Cognitive Impairment Associated with Schizophrenia in Nonsmokers: Results from a Randomized Controlled Phase 2b Study.
Topics: Adult; Aged; Cognition Disorders; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Medication Adherence; Middle Aged; Neuropsychological Tests; Nicotinic Agonists; Quinuclidines; Schizophrenia; Schizophrenic Psychology; Thiadiazoles; Treatment Outcome; Young Adult | 2016 |
ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Cholinergic Agonists; Cholinesterase Inhibitors; Cognition Disorders; Donepezil; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Indans; Male; Mental Status Schedule; Middle Aged; Piperidines; Quinuclidines; Thiadiazoles; Treatment Outcome | 2016 |
Exploratory pilot study assessing the risk of cognitive impairment or sedation in the elderly following single doses of solifenacin 10 mg.
Topics: Aged; Attention; Cognition; Cognition Disorders; Cross-Over Studies; Executive Function; Female; Humans; Hypnotics and Sedatives; Learning; Male; Mandelic Acids; Memory; Memory, Short-Term; Muscarinic Antagonists; Neuropsychological Tests; Parasympatholytics; Pilot Projects; Quinuclidines; Reaction Time; Risk; Sample Size; Solifenacin Succinate; Tetrahydroisoquinolines | 2009 |
11 other study(ies) available for quinuclidines and Cognition Disorders
| Article | Year |
|---|---|
Bis(het)aryl-1,2,3-triazole quinuclidines as α7 nicotinic acetylcholine receptor ligands: Synthesis, structure affinity relationships, agonism activity, [
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Brain; Cell Survival; Cognition Disorders; Dose-Response Relationship, Drug; Fluorine Radioisotopes; Isotope Labeling; Ligands; Molecular Structure; Nicotinic Agonists; Positron-Emission Tomography; Quinuclidines; Rats; Rats, Wistar; Structure-Activity Relationship; Triazoles; Tumor Cells, Cultured | 2019 |
Selective activation of α7 nicotinic acetylcholine receptor by PHA-543613 improves Aβ25-35-mediated cognitive deficits in mice.
Topics: Aconitine; alpha7 Nicotinic Acetylcholine Receptor; Amyloid beta-Peptides; Animals; Bridged Bicyclo Compounds, Heterocyclic; Cholinesterase Inhibitors; Cognition Disorders; Disease Models, Animal; Galantamine; Gene Expression Regulation; Male; Maze Learning; Mice; Mice, Inbred BALB C; Nicotinic Agonists; Nicotinic Antagonists; Peptide Fragments; Psychomotor Performance; Quinuclidines; RNA, Messenger; Time Factors | 2015 |
The Novel, Nicotinic Alpha7 Receptor Partial Agonist, BMS-933043, Improves Cognition and Sensory Processing in Preclinical Models of Schizophrenia.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Cognition Disorders; Drug Evaluation, Preclinical; HEK293 Cells; Humans; Male; Mice; Patch-Clamp Techniques; Quinuclidines; Radioligand Assay; Rats; Schizophrenia; Spiro Compounds | 2016 |
TC-5619: an alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Antipsychotic Agents; Behavior, Animal; Benzofurans; Clozapine; Cognition Disorders; Exploratory Behavior; Female; Male; Maze Learning; Mice; Mice, Transgenic; Neurons; Nicotinic Agonists; Promoter Regions, Genetic; Quinuclidines; Rats; Rats, Sprague-Dawley; Receptor, Fibroblast Growth Factor, Type 1; Receptors, Nicotinic; Reflex, Startle; Schizophrenia; Schizophrenic Psychology; Social Behavior; Tyrosine 3-Monooxygenase | 2009 |
Evaluation of brain anticholinergic activities of urinary spasmolytic drugs using a high-throughput radio receptor bioassay.
Topics: Benzhydryl Compounds; Benzofurans; Biological Assay; Brain; Cognition Disorders; Cresols; Humans; In Vitro Techniques; Mandelic Acids; Muscarinic Antagonists; Phenylpropanolamine; Pyrrolidines; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate | 2011 |
Discovery of (2S,3R)-N-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]benzo[b]furan-2-carboxamide (TC-5619), a selective α7 nicotinic acetylcholine receptor agonist, for the treatment of cognitive disorders.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Benzofurans; CHO Cells; Cognition Disorders; Cricetinae; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Models, Molecular; Molecular Structure; Quinuclidines; Rats; Receptors, Nicotinic; Structure-Activity Relationship | 2012 |
(R)-3'-(3-methylbenzo[b]thiophen-5-yl)spiro[1-azabicyclo[2,2,2]octane-3,5'-oxazolidin]-2'-one, a novel and potent alpha7 nicotinic acetylcholine receptor partial agonist displays cognitive enhancing properties.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Biological Availability; Cerebral Cortex; Cognition; Cognition Disorders; Dopamine; Evoked Potentials, Auditory; Haplorhini; Hippocampus; In Vitro Techniques; Male; Maze Learning; Membrane Potentials; Neurons; Nicotinic Agonists; Nootropic Agents; Oxazoles; Patch-Clamp Techniques; Quinuclidines; Radioligand Assay; Rats; Rats, Wistar; Receptors, Nicotinic; Stereoisomerism; Structure-Activity Relationship | 2006 |
Discovery of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an agonist of the alpha7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia: synthesis and structure--activity relationsh
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Biological Availability; Brain; Bridged Bicyclo Compounds, Heterocyclic; Cognition Disorders; Drug Stability; Ether-A-Go-Go Potassium Channels; Evoked Potentials, Auditory; Humans; In Vitro Techniques; Learning; Male; Memory; Microsomes, Liver; Neurons; Nicotinic Agonists; Nootropic Agents; Patch-Clamp Techniques; Quinuclidines; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptors, Nicotinic; Recognition, Psychology; Schizophrenia; Stereoisomerism; Structure-Activity Relationship | 2006 |
The novel alpha7 nicotinic acetylcholine receptor agonist N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-[2-(methoxy)phenyl]-1-benzofuran-2-carboxamide improves working and recognition memory in rodents.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Benzofurans; Bridged Bicyclo Compounds, Heterocyclic; Cognition Disorders; Exploratory Behavior; Generalization, Psychological; Male; Maze Learning; Memory; Mice; Nicotinic Agonists; Quinuclidines; Rats; Rats, Inbred BN; Rats, Inbred F344; Rats, Wistar; Receptors, Nicotinic | 2007 |
(+-)-cis-2-methyl-spiro(1,3-oxathiolane-5,3')quinuclidine, an M1 selective cholinergic agonist, attenuates cognitive dysfunctions in an animal model of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Avoidance Learning; Binding, Competitive; Cognition Disorders; Copper; Disease Models, Animal; Male; Memory; Mice; Motor Activity; Parasympathomimetics; Pilocarpine; Quinuclidines; Quinuclidinyl Benzilate; Receptors, Muscarinic; Thiophenes | 1991 |
(+-)-cis-2-methyl-spiro(1,3-oxathiolane-5,3') quinuclidine (AF102B): a new M1 agonist attenuates cognitive dysfunctions in AF64A-treated rats.
Topics: Alzheimer Disease; Animals; Aziridines; Behavior, Animal; Choline; Cognition Disorders; Disease Models, Animal; Drug Design; Male; Molecular Structure; Parasympathomimetics; Quinuclidines; Rats; Rats, Inbred Strains; Receptors, Muscarinic; Thiophenes | 1989 |